Modified phospholipids as anti-inflammatory compounds

Current Opinion in Lipidology

Volumn 21, Issue 6, 2010, Pages 525-529

  Feige, Erez ^a   Mendel, Itzhak ^a   George, Jacob ^a   Yacov, Niva ^a   Harats, Dror ^a  

^a VBL Therapeutics   (Israel)

Author keywords

drug development; inflammation; Lecinoxoids; oxidized phospholipids; OxPAPC

Indexed keywords

1 PALMITOYL 1,2 GLUTAROYL SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 (5 HYDROXY 8 OXOOCT 6 ENOYL) SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 (5 OXOVALEROYL) SN GLYCERO PHOSPHOCHOLINE; 1 PALMITOYL 2 (5,6 EPOXYCYCLOPENTENONE) SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 (5,6 EPOXYISOPROSTANE E2) SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 ARACHIDONYL SN GLYCERO 3 PHOSPHORYLCHOLINE; ANTIINFLAMMATORY AGENT; GLYCEROPHOSPHORYLCHOLINE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED PHOSPHOLIPID; PHOSPHOLIPID; PHOSPHOLIPID DERIVATIVE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VB 201;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; CELL FUNCTION; CHRONIC INFLAMMATION; DENDRITIC CELL; EPIGENETICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; INFLAMMATION; MICE; MULTIPLE SCLEROSIS; OXIDATION-REDUCTION; PHOSPHOLIPIDS; PSORIASIS; RABBITS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

ANIMALIA;

EID: 78650307076     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833f2fcb     Document Type: Review

References (40)

1. Fruhwirth GO, Loidl A, Hermetter A. Oxidized phospholipids: from molecular properties to disease. Biochim Biophys Acta 2007; 1772:718-736.
2. Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J Lipid Res 2009; 50 (Suppl):S207-S212.
3. Fraley AE, Schwartz GG, Olsson AG, et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol 2009; 53:2186-2196.
4. Fu P, Birukov KG. Oxidized phospholipids in control of inflammation and endothelial barrier. Transl Res 2009; 153:166-176.
5. Singleton PA, Chatchavalvanich S, Fu P, et al. Akt-mediated transactivation of the S1P1 receptor in caveolin-enriched microdomains regulates endothelial barrier enhancement by oxidized phospholipids. Circ Res 2009; 104:978-986.
6. Fessel JP, Porter NA, Moore KP, et al. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci USA 2002; 99:16713-16718.
7. Wong CH, Heit B, Kubes P. Molecular regulators of leucocyte chemotaxis during inflammation. Cardiovasc Res 2010; 86:183-191.
8. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7:77-86.
9. Subbanagounder G, Deng Y, Borromeo C, et al. Hydroxy alkenal phospholipids regulate inflammatory functions of endothelial cells. Vascul Pharmacol 2002; 38:201-209.
10. Gharavi NM, AlvaJA, Mouillesseaux KP, et al. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 2007; 282:31460-31468.
11. Boullier A, Friedman P, Harkewicz R, et al. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res 2005; 46:969-976.
12. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11:155-161.
13. Harb D, Bujold K, Febbraio M, et al. The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation. Cardiovasc Res 2009; 83:42-51.
14. Chang MK, Binder CJ, Miller YI, et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004; 200: 1359-1370.
15. Yang LV, Radu CG, Wang L, et al. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood 2005; 105:1127-1134.
16. Peter C, Waibel M, Radu CG, et al. Migration to apoptotic 'find-me' signals is mediated via the phagocyte receptor G2A. J Biol Chem 2008; 283:5296-5305.
17. Tan M, Hao F, Xu X, et al. Lysophosphatidylcholine activates a novel PKD2-mediated signaling pathway that controls monocyte migration. Arterioscler Thromb Vasc Biol 2009; 29:1376-1382.
18. Chaudhuri P, Colles SM, Fox PL, Graham LM. Protein kinase Cdelta-depen-dent phosphorylation of syndecan-4 regulates cell migration. Circ Res 2005; 97:674-681.
19. Chan LC, Peters W, Xu Y, et al. LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J Leukoc Biol 2007; 82:1193-1200.
20. Li S, Zhang J. Lipopolysaccharide induces autotaxin expression in human monocytic THP-1 cells. Biochem Biophys Res Commun 2009; 378:264-268.
21. Bochkov VN, Kadl A, Huber J, et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002; 419:77-81.
22. Walton KA, Cole AL, Yeh M, et al. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol 2003; 23:1197-1203.
23. von Schlieffen E, Oskolkova OV, Schabbauer G, et al. Multihit inhibition of circulating and cell-associated omponents of the toll-like receptor 4 pathway by oxidized phospholipids. Arterioscler Thromb Vasc Biol 2009; 29:356-362.
24. Erridge C, Kennedy S, Spickett CM, Webb DJ. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J Biol Chem 2008; 283:24748-24759.
25. Bluml S, KirchbergerS, Bochkov VN, et al. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol 2005; 175:501-508.
26. Bluml S, Zupkovitz G, Kirchberger S, et al. Epigenetic regulation of dendritic cell differentiation and function by oxidized phospholipids. Blood 2009; 114:5481-5489.
27. Ghisletti S, Huang W, Jepsen K, et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev 2009; 23:681-693.
28. Seyerl M, Bluml S, KirchbergerS, et al. Oxidized phospholipids induce anergy in human peripheral blood T cells. Eur J Immunol 2008; 38:778-787.
29. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010; 10:365-376.
30. Leitinger N, Tyner TR, Oslund L, et al. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci USA 1999; 96:12010-12015.
31. Gruber F, Oskolkova O, Leitner A, et al. Photooxidation generates biologically active phospholipids that induce heme oxygenase-1 in skin cells. J Biol Chem 2007; 282:16934-16941.
32. Li C, Hossieny P, Wu BJ, et al. Pharmacologic induction of heme oxygenase-1. Antioxid Redox Signal 2007; 9:2227-2239.
33. Birukov KG, Bochkov VN, Birukova AA, et al. Epoxycyclopentenone-contain- ing oxidized phospholipids restore endothelial barrier function viaCdc42 and Rac. Circ Res 2004; 95:892-901.
34. Zimman A, Chen SS, Komisopoulou E, et al. Activation of aortic endothelial cells by oxidized phospholipids: a phosphoproteomic analysis. J Proteome Res 2010; 9: 2812-2824.
35. Subbanagounder G, Wong JW, Lee H, et al. Epoxyisoprostane and epoxy-cyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem 2002; 277:7271-7281.
36. Lee S, Li R, Kim B, et al. Ox-PAPC activation of PMET system increases expression of heme oxygenase-1 in human aortic endothelial cell. J Lipid Res 2009; 50:265-274.
37. Pidkovka NA, Cherepanova OA, Yoshida T, et al. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res 2007; 101:792-801.
38. Cherepanova OA, Pidkovka NA, Sarmento OF, et al. Oxidized phospholipids induce type VIII collagen expression and vascular smooth muscle cell migration. Circ Res 2009; 104:609-618.
39. Walton KA, Gugiu BG, Thomas M, et al. A role for neutral sphingomyelinase activation in the inhibition of LPS action by phospholipid oxidation products. J Lipid Res 2006; 47:1967-1974.
40. Mendel I, Shoham A, Propheta-Meiran O, et al. A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease. J Neuroimmunology 2010; (in press). PMID: 20663571, doi:10.1016/j.jneuroim.2010. 06.011)